<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01637805</url>
  </required_header>
  <id_info>
    <org_study_id>CIH-ZRP-201205001</org_study_id>
    <nct_id>NCT01637805</nct_id>
  </id_info>
  <brief_title>Clinical Safety and Preliminary Efficacy of AAV-DC-CTL Treatment in Stage IV Gastric Cancer</brief_title>
  <acronym>AAV-DC-CTL</acronym>
  <official_title>Phase 1 Study of Antigen-specific Cytotoxic T Lymphocytes Induced by Dendritic Cells Infected by Recombinant Adeno-associated Virus With CEA Gene in Stage IV Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical safety and preliminary efficacy of&#xD;
      antigen-specific cytotoxic T lymphocytes induced by dendritic cells infected by recombinant&#xD;
      adeno-associated virus with CEA gene in the treatment of stage IV gastric cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>CR + PR = ORR</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Stage IV Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>AAV-DC-CTL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Antigen-specific cytotoxic T lymphocytes induced by dendritic cells infected by recombinant adeno-associated virus with CEA gene</intervention_name>
    <description>AAV-DC-CTL: Intravenous infusion, 1×109 cells, day 14; one cycle every month; at least one cycle</description>
    <arm_group_label>AAV-DC-CTL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sex: male or female&#xD;
&#xD;
          -  Age: from 18 to 80 years&#xD;
&#xD;
          -  Histology: gastric cancer&#xD;
&#xD;
          -  Clinical stage: stage IV&#xD;
&#xD;
          -  Karnofsky performance status: more than 50%&#xD;
&#xD;
          -  Expected survival: more than 2 months&#xD;
&#xD;
          -  Sex: male or female&#xD;
&#xD;
          -  Laboratory tests results 7 days before the start of treatment:&#xD;
&#xD;
               -  White blood cells: more than 3.0 × 109/L&#xD;
&#xD;
               -  Platelets: more than 100 × 109/L&#xD;
&#xD;
               -  Neutrophils: more than 1.5 × 109/L&#xD;
&#xD;
               -  Hemoglobin: more than 80g/L&#xD;
&#xD;
               -  Serum glutamate pyruvate transaminase: less than 2.5 folds of the upper normal&#xD;
                  limit (ULN)&#xD;
&#xD;
               -  Serum glutamic-oxal (o) acetic transaminase: less than 2.5 × ULN&#xD;
&#xD;
               -  Serum bilirubin: less than 1.25 × ULN&#xD;
&#xD;
               -  Serum creatinine: less than 1.25 × ULN&#xD;
&#xD;
          -  Pregnancy test: the test of women of child-bearing period must be negative 7 days&#xD;
             before the start of treatment&#xD;
&#xD;
          -  Contraception: male and female subjects of child-bearing period must adopt a reliable&#xD;
             method of contraception before entry into this study until 30 days after stopping this&#xD;
             study&#xD;
&#xD;
          -  Informed consent: subject must have the ability to understand and voluntarily sign a&#xD;
             written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of neoplasms: other neoplasms&#xD;
&#xD;
          -  Medical history: mental disease, or congestive heart failure, or severe coronary&#xD;
             artery disease, or cardiac arrhythmias, or concomitant corticosteroid therapy&#xD;
&#xD;
          -  Metastasis: clinical symptoms of brain metastasis&#xD;
&#xD;
          -  Other clinical trial: the subject received other clinical trial before this study&#xD;
&#xD;
          -  Laboratory tests: the serum test of human immunodeficiency virus, or hepatitis B&#xD;
             virus, or hepatitis C virus was positive&#xD;
&#xD;
          -  Woman: pregnant or lactating women&#xD;
&#xD;
          -  Compliance: poor compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>July 3, 2012</study_first_submitted>
  <study_first_submitted_qc>July 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2012</study_first_posted>
  <last_update_submitted>March 7, 2016</last_update_submitted>
  <last_update_submitted_qc>March 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

